ストックスクリーナーアプリを入手
4.81
1.91%
0.09
アフターアワーズ：
5.00
0.19
+3.95%
前日終値:
$4.72
開ける：
$4.77
24時間の取引高:
119.80K
Relative Volume:
0.82
時価総額：
$20.42M
収益：
-
当期純損益:
$-21.21M
株価収益率:
-0.1475
EPS:
-32.6
ネットキャッシュフロー:
$-16.86M
1週間 パフォーマンス:
+8.58%
1か月 パフォーマンス:
+8.09%
6か月 パフォーマンス:
+1.05%
1年 パフォーマンス:
+16.52%
1日の値動き範囲:
$4.65
$5.00
1週間の範囲:
$4.25
$5.00
52週間の値動き範囲:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
CING を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.81 | 18.81M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | ROTH MKM | Buy |
| 2023-12-22 | ダウングレード | Laidlaw | Buy → Hold |
Cingulate Inc (CING) 最新ニュース
What makes Cingulate Inc. Equity Warrant stock attractive to long term investorsFree Stock Market Swing Trading Strategies - Newser
Why Cingulate Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Newser
How Cingulate Inc. stock performs during market volatilityFree Market Analysis Group - Newser
Why Cingulate Inc. Equity Warrant stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
How Cingulate Inc. Equity Warrant stock performs during market volatilityFree Stock Index Interpretation - Newser
What makes Cingulate Inc. Equity Warrant stock price move sharplyShort Term Risk Controlled Alerts - Newser
What makes Cingulate Inc. stock price move sharplyFree Stock Movement Tracking - Newser
Cingulate hires chief legal officer ahead of filing for FDA approval - The Business Journals
Cingulate appoints Nilay Patel as Chief Legal Officer - TipRanks
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing By Investing.com - Investing.com South Africa
Cingulate Inc. Appoints Nilay Patel as Chief Legal Officer - MarketScreener
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing - Investing.com
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application - GlobeNewswire
Cingulate Bolsters Executive Team With Key Legal Hire as ADHD Drug Heads to FDA Review - Stock Titan
Cingulate (NASDAQ:CING) Stock Price Up 3.3% – Here’s What Happened - Defense World
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView
Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan
Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com
Cingulate Inc. expands equity plan following stockholder approval - Investing.com
Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks
Cingulate Inc. expands equity plan following stockholder approval By Investing.com - Investing.com India
Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow
CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus
Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan
What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World
McCann Joburg acquires a healthcare marketing company - Bizcommunity
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq
Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire
CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus
Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
CING: First Quarter 2025 Results - Yahoo Finance
Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada
Anchoring Your Portfolio: Is CING Stock a Safe Harbor? - investchronicle.com
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks
Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus
Cingulate receives FDA meeting feedback on ADHD drug - Investing.com
Cingulate Inc (CING) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):